The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) have issued a new procedure standard/practice guideline for estrogen receptor imaging of breast cancer patients using FES PET.

Getty Images


January 16, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) have issued a new procedure standard/practice guideline for estrogen receptor imaging of breast cancer patients using FES PET. The standard/guideline, published ahead of print in The Journal of Nuclear Medicine, is intended to assist physicians in recommending, performing, interpreting, and reporting the results of 18F-FES PET studies for patients with breast cancer.

More than two million women worldwide are diagnosed with breast cancer each year. The estrogen receptor (ER) is a significant contributor to breast cancer formation and progression and, as such, is an important target for therapy. Approximately 70 percent of breast cancers will express ER, and the determination of ER expression by tissue analysis is part of the standard of care for those newly diagnosed breast cancer.

Multiple studies suggest that 18F-FES PET—which is approved for clinical use in France and the United States—offers advantages in assessing tumor ER expression, predicting response to ER-targeted therapies, and clarifying equivocal staging and restaging results in patients with ER-expressing cancers. It may also be helpful in staging invasive lobular breast cancer and low-grade ER-expressing invasive ductal cancers and, in some cases, may be a substitute for biopsy.

The procedure guideline/practice standard includes information on common clinical indications, procedure specifications, patient selection and preparation, tracer administration and imaging, and imaging interpretation and reporting. It also presents standardized quality control, quality assurance, and imaging procedures for 18F-FES PET.

“Precision, accuracy, repeatability, and reproducibility for both clinical management of patients and for the use of 18F-FES in multicenter trials is important,” emphasize the authors. “The availability of a standardized imaging procedure will help to promote the appropriate use of 18F-FES PET and enhance subsequent research.”

SNMMI/EANM periodically define new standards/guidelines for nuclear medicine practice to help advance the science of nuclear medicine and to deliver effective and safe medical care to patients. Each standard/guideline, representing a policy statement by the SNMMI/EANM, undergoes a thorough consensus process in which it is subjected to extensive review.

This article was published online in December 2023.

For more information: www.snmmi.org


Related Content

News | Breast Imaging

June 18, 2024 — Delphinus Medical Technologies, a pioneering medical imaging company that developed the SoftVue Breast ...

Time June 18, 2024
arrow
News | PET-CT

June 13, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 13, 2024
arrow
News | Radiology Business

June 12, 2024 — Cathy Sue Cutler, PhD, FSNMMI, chair of the Isotope Research and Production Department at Brookhaven ...

Time June 12, 2024
arrow
News | MRI Breast

June 12, 2024 — Royal Philips recently announced the 1,111th installation of its revolutionary BlueSeal 1.5T magnet ...

Time June 12, 2024
arrow
News | SPECT-CT

June 11, 2024 — A newly developed radiotracer can generate high quality and readily interpretable images of cardiac ...

Time June 11, 2024
arrow
News | PET Imaging

June 11, 2024 — A new ultra-high-performance brain PET system allows for the direct measurement of brain nuclei as never ...

Time June 11, 2024
arrow
News | Radiology Business

June 10, 2024 — Jean-Luc C. Urbain, MD, PhD, FASNC, professor of Radiology/Nuclear Medicine and Medicine, has been named ...

Time June 10, 2024
arrow
News | Radiology Business

June 10, 2024 — Carolyn J. Anderson, PhD, a trailblazer in nuclear medicine, has been named the 2024 recipient of the ...

Time June 10, 2024
arrow
News | FDA

June 10, 2024 — Siemens Healthineers announces the Food and Drug Administration clearance of the Biograph Trinion, a ...

Time June 10, 2024
arrow
News | Breast Imaging

June 7, 2024 — Scholars and studies funded by Susan G. Komen(R), the world’s leading breast cancer organization ...

Time June 07, 2024
arrow
Subscribe Now